弥漫性肝病的胶原靶向分子影像
本文综述了以I型胶原为靶点的分子影像在弥漫性肝病中的应用。I型胶原过度沉积对纤维化具有特异性,其浓度适合多种影像模态;新型胶原靶向分子MRI对比剂可直接定量胶原沉积,并已在多种动物种属和肝损伤模型中得到验证。胶原靶向分子影像有望用于纤维化初始分期、进展监测及药物试验中的纤维化逆转标志物。
要点
- I型胶原过度沉积对纤维化具有特异性,是分子影像的 attractive 靶点。
- 胶原靶向分子MRI对比剂可直接定量胶原沉积,已在动物种属和肝损伤模型验证。
- 胶原靶向分子影像有望用于纤维化分期、进展监测和药物试验中的逆转标志物。
核心结论
- 胶原靶向分子影像探针不仅有望作为纤维化初始分期和进展监测的工具,还可作为药物试验中纤维化逆转的标志物。
研究设计与样本
- 本文为综述,检索范围与纳入文献原文未报告。
临床应用与阅片要点
- 作者认为,胶原靶向分子影像探针有望用于纤维化初始分期、进展监测以及药物试验中作为纤维化逆转的标志物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Liver fibrosis is a common pathway shared by all progressive chronic liver diseases (CLD) regardless of the underlying etiologies. With liver biopsy being the gold standard in assessing fibrosis degree, there is a large unmet clinical need to develop non-invasive imaging tools that can directly and repeatedly quantify fibrosis throughout the liver for a more accurate assessment of disease burden, progression, and treatment response. Type I collagen is a particularly attractive target for molecular imaging as its excessive deposition is specific to fibrosis, and it is present in concentrations suitable for many imaging modalities. Novel molecular MRI contrast agents designed to bind with collagen provide direct quantification of collagen deposition, which have been validated across animal species and liver injury models. Collagen-targeted molecular imaging probes hold great promise not only as a tool for initial staging and surveillance of fibrosis progression, but also as a marker of fibrosis regression in drug trials.
引用
- Zhou IY, Tanabe KK, Fuchs BC, et al. Collagen-targeted molecular imaging in diffuse liver diseases. Abdom Radiol (NY). 2020. PMID: 32737546. doi:10.1007/s00261-020-02677-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。